← Back to home

Locally advanced or metastatic KRAS G12C-mutated NSCLC with A PD-L1 expression <1% or A PD-L1 expression ≥ 1% and an STK11 co-mutation

Clinical trials for Locally advanced or metastatic KRAS G12C-mutated NSCLC with A PD-L1 expression <1% or A PD-L1 expression ≥ 1% and an STK11 co-mutation explained in plain language.

Never miss a new study

Get alerted when new Locally advanced or metastatic KRAS G12C-mutated NSCLC with A PD-L1 expression <1% or A PD-L1 expression ≥ 1% and an STK11 co-mutation trials appear

Sign up with your email to follow new studies for Locally advanced or metastatic KRAS G12C-mutated NSCLC with A PD-L1 expression <1% or A PD-L1 expression ≥ 1% and an STK11 co-mutation, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

New hope for Hard-to-Treat lung cancer: targeted pill shows promise

Disease control Ongoing

This study tests a new drug called JDQ443 in people with advanced lung cancer that has a specific genetic change (KRAS G12C mutation) and does not respond well to standard treatments. The drug is taken as a pill and aims to shrink or control the cancer. About 95 participants will…

Matched conditions: LOCALLY ADVANCED OR METASTATIC KRAS G12C-MUTATED NSCLC WITH A PD-L1 EXPRESSION <1% OR A PD-L1 EXPRESSION ≥ 1% AND AN STK11 CO-MUTATION

Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control

Last updated Sep 12, 2026 00:00 UTC

Locally advanced or metastatic KRAS G12C-mutated NSCLC with A PD-L1 expression <1% or A PD-L1 expression ≥ 1% and an STK11 co-mutation

Get alerted when new Locally advanced or metastatic KRAS G12C-mutated NSCLC with A PD-L1 expression <1% or A PD-L1 expression ≥ 1% and an STK11 co-mutation trials appear

New hope for Hard-to-Treat lung cancer: targeted pill shows promise